These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35675209)

  • 1. Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
    Yu X; Cheng M; Lu K; Shen Y; Zhong Y; Liu J; Xiong Y; Jin J
    J Med Chem; 2022 Jun; 65(12):8416-8443. PubMed ID: 35675209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
    Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
    Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation.
    Chung C; Yoo G; Kim T; Lee D; Lee CS; Cha HR; Park YH; Moon JY; Jung SS; Kim JO; Lee JC; Kim SY; Park HS; Park M; Park DI; Lim DS; Jang KW; Lee JE
    Biochem Biophys Res Commun; 2016 Oct; 479(2):152-158. PubMed ID: 27475501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
    Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
    Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
    Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
    Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent small molecule PROTACs targeting mutant EGFR.
    Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK.
    Lin Q; Wang J; Childress C; Sudol M; Carey DJ; Yang W
    Mol Cell Biol; 2010 Mar; 30(6):1541-54. PubMed ID: 20086093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
    Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
    J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
    Mahan SD; Riching KM; Urh M; Daniels DL
    Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
    Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
    Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
    Chaudhry C
    J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
    Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
    Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
    Wang H; Li C; Liu X; Ma M
    Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of highly potent and selective CRBN-recruiting EGFR
    Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
    Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.